Clinical trial
The "PASSPORT Trial": Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active Crohn's Disease or Ulcerative Colitis.
NCT06274294 is registered in ClinicalTrials.gov with CMC Ambroise Paré as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The "PASSPORT Trial": Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active Crohn's Disease or Ulcerative Colitis.
- Lead sponsor
- CMC Ambroise Paré
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- July 10, 2024
- Completion date
- January 31, 2025
- Enrollment
- 130 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.